CNPY2 and hepatocellular carcinoma: Intratumoral administration of nanoparticle‐based CRISPR/Cas9 targeting Canopy homolog 2 (CNPY2), a critical UPR promoter, has demonstrated significant antitumor effects in HCC tumors [218].